

July 26, 2011

Roche Diagnostics showcases new technology at Clinical Lab Expo

Laboratory solutions designed to help improve productivity, enhance patient care

ATLANTA—Roche is featuring a diverse portfolio of diagnostics testing solutions for healthcare professionals in booth #2205 at the AACC/CSCC 2011 Clinical Lab Expo here, July 26-29.

The Roche booth will feature a variety of new technology for hospital and laboratory testing, including integrated clinical chemistry and immunoassay analyzer platforms, automation components, information technology solutions, and chemistry, immunoassay and molecular diagnostics tests.

New products that will be featured in the booth include:

cobas[®] HPV Test

The new **cobas** HPV test allows clinicians to quickly and easily identify patients at highest risk for cervical cancer. It is the only assay that provides specific genotyping information for HPV-16 and 18 – the two genotypes responsible for 70 percent of cervical cancers – while simultaneously reporting the 12 other high-risk HPV types as a pooled result. It runs on the new **cobas** 4800 system and provides clinicians with three results in one test, in one run, from one patient sample (1 mL), eliminating the need for reflex testing. Introduced in April 2011.

cobas® 4800 system

The **cobas®** 4800 system offers true walk-away automation of nucleic acid purification, polymerase chain reaction (PCR) set-up and real-time PCR amplification and detection to help laboratories achieve maximum efficiency. The system needs minimal daily maintenance and requires less hands-on time than most similar systems, freeing staff to spend more time on other critical tasks. It utilizes the AmpErase® enzyme, internal control and a unique kinetic algorithm to deliver consistent, accurate test results. Introduced in April 2011.

cobas e 602 analyzer

An immunoassay analyzer, the **cobas** e 602 analyzer is a component of the **cobas** 8000 modular analyzer series. It uses Roche's patented electrochemiluminescence (ECL) technology, which provides broad measuring ranges and low-end sensitivity, and offers up to 170 tests per hour and an initial menu of over 50 assays. Introduced in October 2010.

cobas c 702 analyzer

The newest member of the **cobas®** 8000 modular analyzer series, the **cobas c** 702 analyzer represents the next generation in high throughput clinical chemistry analyzers, offering up to 2,000 tests per hour. It also offers enhanced reagent management, including automated reagent cassette exchange and reagent decapping, loading and unloading without operator interaction. The analyzer can be combined with the **cobas c** 502 analyzer for mid-volume chemistry and immunoassay testing, or with the **cobas e** 602 analyzer to create an integrated platform with 24 unique system configurations to meet the needs of high-volume laboratories. Introduced in May 2011.

9-Minute STAT Cardiac Assays

9-minute STAT assays for Troponin T, Troponin I, NT-proBNP, CK-MB and Myoglobin provide significant turnaround time improvement for cardiac marker testing on the **cobas** 6000 and **cobas** 8000 analyzer series. On average, they can produce the same critical results in half the time of the standard assays. In addition, they only require one simple blood draw, obtained with the Roche OneTUBE® solution – a faster, more efficient way to deliver accurate results without sacrificing performance, precision or sensitivity. Introduced in October 2010.

Roche Elecsys Human Growth Hormone (hGH) Assay

The Roche Elecsys Human Growth Hormone assay is an electrochemiluminescence (ECL) immunoassay for the quantitative determination of the biologically active 20 kDA and 22kDA

isoforms of human growth hormone in serum and plasma. The one-step assay, available for the **MODULAR ANALYTICS E 170** module and the **cobas e 601** and **cobas e 602** analyzers, has a duration time of only 18 minutes and demonstrates excellent total precision of 1.7-2.6 CV%, helping to provide a solid base for a growth hormone assessment. Introduced in April 2011.

Roche Elecsys Anti-HAV Assay

The Roche Elecsys Anti-HAV assay is an electrochemiluminescence (ECL) immunoassay for the in-vitro qualitative detection of total antibodies (IgM and IgG) to hepatitis A virus in human serum and plasma. The assay is intended for use as an aid in the laboratory diagnosis of past or acute/recent hepatitis A infection. The Roche Anti-HAV assay is intended for use on the **MODULAR ANALYTICS E 170** module and the **cobas e 601**, **cobas e 602**, **cobas e 411** and Elecsys 2010 instruments. Introduced in December 2010.

Roche Elecsys Tg Assay

The Roche Elecsys Tg assay is an electrochemiluminescence (ECL) immunoassay for the quantitative determination of Thyroglobulin in human serum and plasma. Determination of Tg is used as an aid in monitoring for the presence of local and metastatic thyroid tissue in patients who have had thyroid ablation. The Roche Thyroglobulin assay is intended for use on the **MODULAR ANALYTICS E 170** module and the **cobas e 601**, **cobas e 602**, **cobas e 411** and Elecsys 2010 instruments. Introduced in September 2010.

Roche Middleware Solutions – Moving Averages

Roche Middleware Solutions now includes a Moving Averages feature to help laboratories monitor patient results between quality control runs. The new functionality helps labs detect potential assay or instrument degradation to help avoid QC failure. Introduced in July 2010.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees

worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Betsy Cox
Director, Corporate Communications
Roche Diagnostics Corporation
Indianapolis, IN
(317) 521-3911
betsy.cox@roche.com